CR10789A - Inhibidores nucleosidicos del hcv - Google Patents

Inhibidores nucleosidicos del hcv

Info

Publication number
CR10789A
CR10789A CR10789A CR10789A CR10789A CR 10789 A CR10789 A CR 10789A CR 10789 A CR10789 A CR 10789A CR 10789 A CR10789 A CR 10789A CR 10789 A CR10789 A CR 10789A
Authority
CR
Costa Rica
Prior art keywords
hcv
nucleosidic inhibitors
nucleosidic
inhibitors
hcv nucleosidic
Prior art date
Application number
CR10789A
Other languages
English (en)
Inventor
Nils-Gunnar Johansson
Genadiy Kalayanov
Joseph Armstrong Martin
David Bernard Smith
Anna Winqvist
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of CR10789A publication Critical patent/CR10789A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR10789A 2006-10-10 2009-05-11 Inhibidores nucleosidicos del hcv CR10789A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85092606P 2006-10-10 2006-10-10

Publications (1)

Publication Number Publication Date
CR10789A true CR10789A (es) 2009-09-14

Family

ID=38925483

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10789A CR10789A (es) 2006-10-10 2009-05-11 Inhibidores nucleosidicos del hcv

Country Status (31)

Country Link
US (4) US7666856B2 (es)
EP (2) EP2084175B1 (es)
JP (2) JP2010505902A (es)
KR (1) KR20090078347A (es)
CN (2) CN101573370B (es)
AP (1) AP2009004812A0 (es)
AT (1) ATE493428T1 (es)
AU (1) AU2007306405A1 (es)
BR (1) BRPI0719258A2 (es)
CA (1) CA2665049C (es)
CO (1) CO6180441A2 (es)
CR (1) CR10789A (es)
CY (1) CY1111342T1 (es)
DE (1) DE602007011658D1 (es)
DK (1) DK2084175T3 (es)
EA (1) EA018935B1 (es)
ES (2) ES2358853T3 (es)
GT (1) GT200900069A (es)
HN (1) HN2009000614A (es)
HR (1) HRP20110193T1 (es)
IL (1) IL197907A0 (es)
MX (1) MX2009003452A (es)
MY (1) MY145314A (es)
NO (1) NO20091834L (es)
NZ (1) NZ575889A (es)
PL (2) PL2361922T3 (es)
PT (1) PT2084175E (es)
RS (1) RS51643B (es)
SI (1) SI2084175T1 (es)
WO (1) WO2008043704A1 (es)
ZA (1) ZA200902496B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003452A (es) * 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
TW201012814A (en) * 2008-07-01 2010-04-01 Centocor Ortho Biotech Products L P Cyclopropyl polymerase inhibitors
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
EP2166016A1 (en) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
DE102009028015A1 (de) * 2009-07-24 2011-01-27 Virologik Gmbh Mittel zur Behandlung von Hepatitis C-Infektionen
WO2011039221A2 (en) 2009-09-29 2011-04-07 Centocor Ortho Biotech Products L.P. Phosphoramidate derivatives of nucleosides
NZ602552A (en) 2010-04-13 2014-09-26 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339752A (ja) 1986-08-02 1988-02-20 Kawada Tekko Kk インデツクス装置
SE8701605D0 (sv) 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
DE3715666A1 (de) 1987-05-11 1988-11-24 Kodak Ag Kassettenentlade- und beladegeraet
GB8712115D0 (en) 1987-05-22 1987-06-24 Hoffmann La Roche Pyrimidine derivatives
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
NO171507C (no) * 1988-11-21 1993-03-24 Syntex Inc Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater
US5034518A (en) 1989-05-23 1991-07-23 Southern Research Institute 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
JPH04506461A (ja) 1990-03-30 1992-11-12 イーストマン ケミカル カンパニー アセテートとの反応によるアルコール―エステル分離
AU7623991A (en) * 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US5418151A (en) 1992-08-07 1995-05-23 Genencor International, Inc. Regio-selective process for resolution of carbohydrate monoesters
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
EP1058686B1 (en) 1998-02-25 2006-11-02 Emory University 2'-fluoronucleosides
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000069877A1 (en) 1999-05-12 2000-11-23 Yamasa Corporation 4'-c-ethynyl purine nucleosides
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
JP3373502B2 (ja) 1999-12-24 2003-02-04 旭硝子株式会社 窒化ケイ素フィルタおよびその製造法
AU2001253206A1 (en) 2000-04-05 2001-10-23 Tularik, Inc. Ns5b hcv polymerase inhibitors
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
PY0111577A (es) * 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002005787A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Fabrication pour produits lyophilises
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
US6677120B2 (en) 2001-03-30 2004-01-13 Isis Pharmaceuticals, Inc. Building blocks for the solution phase synthesis of oligonucleotides
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002344854B2 (en) 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
AU2002361518A1 (en) 2001-12-18 2003-06-30 Gustavo Fernandez Del Castillo Y Simon Column-type multi-piston
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
EP1525209B1 (en) 2002-06-28 2017-11-15 Idenix Pharmaceuticals LLC 1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004041818A1 (en) 2002-11-01 2004-05-21 Abbott Laboratories Anti-infective agents
NO319194B1 (no) 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
AU2003300957A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
WO2004052312A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
AU2003297235A1 (en) 2002-12-17 2004-07-22 Smithkline Beecham Corporation Anti-infectives
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
KR20060026426A (ko) 2003-06-19 2006-03-23 에프. 호프만-라 로슈 아게 4'-아지도 뉴클레오사이드 유도체의 제조 방법
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
DE602005015466D1 (de) * 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
RU2007110531A (ru) 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
MX2009003452A (es) * 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.

Also Published As

Publication number Publication date
EP2361922B1 (en) 2012-08-22
CO6180441A2 (es) 2010-07-19
AP2009004812A0 (en) 2009-04-30
RS51643B (sr) 2011-10-31
CY1111342T1 (el) 2015-08-05
DK2084175T3 (da) 2011-04-18
PL2084175T3 (pl) 2011-06-30
US7825239B2 (en) 2010-11-02
EA018935B1 (ru) 2013-11-29
CA2665049C (en) 2012-12-04
WO2008043704A1 (en) 2008-04-17
CN101573370A (zh) 2009-11-04
JP2010505902A (ja) 2010-02-25
DE602007011658D1 (de) 2011-02-10
KR20090078347A (ko) 2009-07-17
HN2009000614A (es) 2011-07-11
GT200900069A (es) 2009-11-06
CN101979397A (zh) 2011-02-23
US7935681B2 (en) 2011-05-03
US8158779B2 (en) 2012-04-17
HRP20110193T1 (hr) 2011-05-31
PT2084175E (pt) 2011-04-01
US20110172410A1 (en) 2011-07-14
HK1154247A1 (en) 2012-04-13
BRPI0719258A2 (pt) 2014-04-29
SI2084175T1 (sl) 2011-05-31
HK1137459A1 (en) 2010-07-30
US20100130735A1 (en) 2010-05-27
AU2007306405A1 (en) 2008-04-17
CN101979397B (zh) 2013-11-06
US20080152621A1 (en) 2008-06-26
JP2011246485A (ja) 2011-12-08
MY145314A (en) 2012-01-13
EP2084175B1 (en) 2010-12-29
IL197907A0 (en) 2009-12-24
PL2361922T3 (pl) 2013-01-31
ATE493428T1 (de) 2011-01-15
ES2358853T3 (es) 2011-05-16
MX2009003452A (es) 2009-04-14
CA2665049A1 (en) 2008-04-17
ZA200902496B (en) 2010-06-30
EA200970358A1 (ru) 2009-12-30
NO20091834L (no) 2009-05-11
EP2361922A1 (en) 2011-08-31
EP2084175A1 (en) 2009-08-05
US7666856B2 (en) 2010-02-23
NZ575889A (en) 2011-09-30
ES2392948T3 (es) 2012-12-17
US20110015148A1 (en) 2011-01-20
CN101573370B (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
CY2017016I2 (el) Αναστολεις πρωτεασωματος
ATE493428T1 (de) Hcv-nukleosidinhibitor
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DE602007008347D1 (de) Koordinateneingabevorrichtung
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE502007000361D1 (de) Stanznieteinheit
DK2066662T3 (da) Serinhydrolaseinhibitorer
FI20061014A0 (fi) Diffuusiopinnoitusmenetelmä
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE502007001652D1 (de) Notöltank
BRPI0719956A2 (pt) Radiofluoração
DE102006045567A8 (de) Crimpstabilisierung
DE502006005977D1 (de) Baugruppenträger
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
DE112007001125A5 (de) Käfigmutter
DE502007001094D1 (de) Hubkupplung
FR2902643B1 (fr) Attelle
ITRM20060031A1 (it) Elettroconduttura
FI20060338A0 (fi) Teline
UA12831S (uk) Стіл

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)